Industry news
Roche acquires Adheron Therapeutics and with it SPD 051
Adheron Therapeutics, a privately held biotechnology company based in Berkeley, California, United States, announced that it has agreed to be acquired by Roche. Adheron Therapeutics has developed a technology that disrupts immune cell adhesion through a cell surface protein called Cadherin-11 in order to develop potential treatments for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic diseases. The lead asset, SDP 051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase I of clinical development.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins